

Profiles

December 17, 2015

DAVID S. JANOWSKY, M.D.

PUBLICATIONS

A. Refereed Journals

1. Janowsky DS, Rosenau W, Moon HD. Isolation of immunologically competent lymphocytes from sensitized mouse spleens. *Proceedings of the Society for Experimental Biology and Medicine*. 1964;115:77-79.
2. Janowsky DS, Gorney R, Kelley B. The Curse - Vicissitudes and variations of the female fertility cycle: Part I., Psychiatric Aspects. *Psychosomatics*. 1966;7:242-247.
3. Gorney R, Janowsky DS, Kelley B. The Curse - Vicissitudes and variations of the female fertility cycle: Part II., Evolutionary Aspects. *Psychosomatics*. 1966;7:283-287.
4. Janowsky DS, Gorney R, Mandell AJ. The Menstrual Cycle: Psychiatric and ovarian-adrenocortical hormone correlates: Case study and literature review. *Archives of General Psychiatry*. 1967;17:459-469.
5. Janowsky DS, Gorney R, Castelnuovo-Tedesco P, Stone CB. Premenstrual-menstrual increases in psychiatric hospital admission rates. *American Journal of Obstetrics and Gynecology*. 1969;103:189-191.
6. Epstein RS, Janowsky DS. Research on the psychiatric ward. *Archives of General Psychiatry*. 1969;21:455-463.
7. Bunney WE, Janowsky DS, Goodwin FK, Davis JM, Brodie HK, Murphy DL, Chase TN. Effect of L-Dopa on depression. *Lancet*. 1969;1:885-886 (letter).
8. Paul MI, Ditzion BR, Pauk GL, Janowsky DS. Urinary adenosine 3',5'-monophosphate excretion in affective disorders. *American Journal of Psychiatry*. 1970;126:1493-1497.
9. Curry SH, Davis JM, Janowsky DS, Marshall JHL. Factors affecting chlorpromazine plasma levels in psychiatric patients. *Archives of General Psychiatry*. 1970;22:209-215.
10. Janowsky DS, Leff M, Epstein RS. Playing the manic game: Interpersonal maneuvers of the acutely manic patient. *Archives of General Psychiatry*. 1970;22:252-261.
11. Curry SH, Marshall JHL, Davis JM, Janowsky DS. Chlorpromazine plasma levels and effects. *Archives of General Psychiatry*. 1970;22:289-296.
12. Janowsky DS, Davis JM. Progesterone-estrogen effects on uptake and release of norepinephrine by synaptosomes. *Life Sciences*. 1970;9:525-531.
13. Castelnuovo-Tedesco P, Schwertfeger HD, Janowsky DS. Psychological characteristics of patients with ulcerative colitis and patients with peptic ulcers: A comparison. *Psychiatry in Medicine*. 1970;1:59-75.

14. Vogel SA, Janowsky DS, Davis JM. Effect of estradiol on stimulus-induced release of ^3H -norepinephrine and ^3H -serotonin from rat brain slices. *Research Communications in Chemical Pathology and Pharmacology*. 1970;1:451-459.
15. Paul MI, Ditzion BR, Janowsky DS. Affective illness and cyclic-AMP excretion. *Lancet*. 1970;1:88 (letter).
16. Decker BL, Davis JM, Janowsky DS, El-Yousef MK, Sekerki HJ. Amantadine hydrochloride treatment of tardive dyskinesia. *New England Journal of Medicine*. 1971;285:860 (letter).
17. Fann WE, Janowsky DS, Davis JM, Oates JA. Chlorpromazine reversal of the antihypertensive action of guanethidine. *Lancet*. 1971;2:436-437 (letter).
18. Janowsky DS, Fann WE, Davis JM. Monoamines and ovarian hormone-linked sexual and emotional changes: A review. *Archives of Sexual Behavior*. 1971;1:205-218.
19. Fann WE, Cavanaugh JH, Kaufmann JS, Griffith JD, Davis JM, Janowsky DS, Oates JA. Doxepin: Effects on transport of biogenic amines in man. *Psychopharmacologia (Berlin)*. 1971;22:111-125.
20. Fann WE, Davis JM, Janowsky DS, Kaufmann JS, Griffith JD, Oates JA. Effect of iprindole on amine uptake in man. *Archives of General Psychiatry*. 1972;26:158-162.
21. Janowsky DS, Davis JM, Fann WE, Freeman J, Nixon R, Michelakis AA. Angiotensin effect on uptake of norepinephrine by synaptosomes. *Life Sciences*. 1972;11:1-11.
22. Fann WE, Davis JM, Janowsky DS, Cavanaugh JH, Kaufmann JS, Griffith JD, Oates JA. Effects of lithium on adrenergic function in man. *Clinical Pharmacology and Therapeutics*. 1972;13:71-77.
23. Fann WE, Davis JM, Janowsky DS. The prevalence of tardive dyskinesias in mental hospital patients. *Diseases of the Nervous System*. 1972;33:182-186.
24. Christoph GW, Schmidt DE, Davis JM, Janowsky DS. A method for determination of chlorpromazine in human blood serum. *Clinica Chimica Acta*. 1972;38:265-270.
25. Rosenblatt JE, Janowsky DS, Davis JM, El-Yousef MK. The augmentation of physostigmine toxicity in the rat by delta-9-tetrahydrocannabinol. *Research Communications in Chemical Pathology and Pharmacology*. 1972;3:479-482.
26. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. *Lancet*. 1972;2:632-635.
27. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. Cholinergic antagonism of methylphenidate-induced stereotyped behavior. *Psychopharmacologia (Berlin)*. 1972;27:295-303.
28. Janowsky DS, El-Yousef MK, Davis JM, Fann WE, Oates JA. Guanethidine antagonism by antipsychotic drugs. *Journal of the Tennessee Medical Association*. 1972;65:620-622.
29. El-Yousef MK, Janowsky DS, Davis JM, Fann WE. Reversal of bztropine toxicity by physostigmine. *Journal of the American Medical Association*. 1972;220:125 (letter).
30. El-Yousef MK, Davis JM, Janowsky DS, Fann WE. Central atropine-like toxicity in combined psychotropic drug administration. *Journal of the Tennessee Medical Association*. 1972;65:719.

31. Janowsky DS, El-Yousef MK, Davis JM, Fann WE. Chlorpromazine - Another guanethidine antagonist. *Journal of the American Medical Association*. 1972;220:1288-1289 (medical news).
32. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ, Morris DR, Decker B. Effects of amantadine on tardive dyskinesia and pseudo-parkinsonism. *New England Journal of Medicine*. 1972;286:785 (letter).
33. Janowsky DS, El-Yousef MK, Davis JM, Hubbard B, Sekerke HJ. Cholinergic reversal of manic symptoms. *Lancet*. 1972;1:1236-1237 (letter).
34. Janowsky DS, Davis JM, El-Yousef MK, Sekerke HJ. Combined anticholinergic agents and atropine-like delirium. *American Journal of Psychiatry*. 1972;129:360-361 (letter).
35. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. *Archives of General Psychiatry*. 1973;28:185-191.
36. El-Yousef MK, Janowsky DS, Davis JM, Rosenblatt JE. Induction of severe depression by physostigmine in marijuana intoxicated individuals. *British Journal of Addiction*. 1973;68:321-325.
37. El-Yousef MK, Janowsky DS, Davis JM, Sekerke HJ. Reversal of antiparkinsonian drug toxicity by physostigmine: A controlled study. *American Journal of Psychiatry*. 1973;130:141-145.
38. Janowsky JS, El-Yousef MK, Davis JM, Sekerke HJ. Parasympathetic suppression of manic symptoms by physostigmine. *Archives of General Psychiatry*. 1973;28:542-547.
39. Janowsky DS, Berens SC, Davis JM. Correlations between mood, weight, and electrolytes during the menstrual cycle: A renin-angiotensin-aldosterone hypothesis of premenstrual tension. *Psychosomatic Medicine*. 1973;35:143-154.
40. Janowsky DS, El-Yousef MK, Davis JM, Fann WE. Antagonism of guanethidine by chlorpromazine. *American Journal of Psychiatry*. 1973;130:808-812.
41. Davis JM, Janowsky DS. Psychopharmacology of methylphenidate in man: Advances in neuropsychopharmacology. *Avicenum Czechoslovak Medical Press*. 1973;511-125.
42. Davis JM, Fann WE, El-Yousef MK, Janowsky DS. Clinical problems in treating the aged with psychotropic drugs. *Advances in Behavioral Biology*. 1973;7:111-125.
43. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. Antagonistic effects of physostigmine and methylphenidate in man. *American Journal of Psychiatry*. 1973;130:1370-1376.
44. Fann WE, Davis JM, Janowsky DS, Sekerke HJ, Schmidt DM. Chlorpromazine: Effects of antacids on its gastrointestinal absorption. *Journal of Clinical Pharmacology*. 1973;13:388-390.
45. Janowsky DS, El-Yousef MK, Davis JM. Interpersonal maneuvers of manic patients. *American Journal of Psychiatry*. 1974;131:250-255.
46. Janowsky DS, El-Yousef MK, Davis JM. Acetylcholine and depression. *Psychosomatic Medicine*. 1974;36:248-257.
47. Davis JM, Janowsky DS. Recent advances in the treatment of depression. *British Journal of Hospital Medicine*. 1974;11:219-228.

48. Nixon RL, Janowsky DS, Davis JM. Effects of progesterone, beta-estradiol, and testosterone on the uptake and metabolism of ³H-norepinephrine, ³H-dopamine and ³H-serotonin in rat brain synaptosomes. *Research Communications in Chemical Pathology and Pharmacology*. 1974;7:233-236.
49. Fann WE, Davis JM, Janowsky DS, Kaufman JF, Cavanaugh JH, Oates JA. Effect of antidepressant and antimanic drugs on amine uptake in man. *Journal of Nervous Mental Disorders*. 1974;158:361-368.
50. Davis JM, Sekerke HJ, Janowsky DS. Drug interactions involving the drugs of abuse. *Drug Intelligence and Clinical Pharmacy*. 1974;8:120-142.
51. Meacham MP, Janowsky DS, Blaine JD, Bozzetti LP, Schorr M. Effects of marijuana on flying ability. *Journal of the American Medical Association*. 1974;230:1258 (letter).
52. Davis JM, Janowsky DS, Sekerke HJ, El-Yousef MK. The psychotropic drugs--Cost effectiveness and clinical pharmacological studies. *Annals of Internal Medicine*. 1974;11:219-228.
53. Shopsin B, Janowsky DS, Davis J, Gershon S. Rebound phenomena in manic patients following physostigmine. *Neuropsychobiology*. 1975;1:180-187.
54. Janowsky DS, Meacham MP, Blaine JD, Schoor M, Bozzetti LP. Marijuana effects on simulated flying ability. *American Journal of Psychiatry*. 1976;133:384-388.
55. Janowsky D, Pechnick R, Janowsky E. Lethal effects of reserpine plus physostigmine and neostigmine in mice. *Clinical and Experimental Pharmacology and Physiology*. 1976;3:483-486.
56. Janowsky DS, Meacham MP, Blaine JD, Schoor M, Bozzetti LP. Simulated flying performance after marijuana intoxication. *Aviation, Space, and Environmental Medicine*. 1976;47:124-128.
57. Leichner PP, Janowsky DS, Reid AE. Intravenous methylphenidate as a diagnostic and psychotherapeutic instrument in adult psychiatry. *Canadian Psychiatric Association Journal*. 1976;21:489-496.
58. Janowsky DS, Janowsky EC. Methscopolamine as a preanesthetic medication. *Canadian Anesthetists' Society Journal*. 1976;23:234-335 (letter).
59. Janowsky DS, Davis JM. Methylphenidate, dextroamphetamine, and levamfetamine: Effects on schizophrenic symptoms. *Archives of General Psychiatry*. 1976;33:304-308.
60. Janowsky DS, Huey L, Storms L, Judd LL. Methylphenidate hydrochloride effects on psychological tests in acute schizophrenic and nonpsychotic patients. *Archives of General Psychiatry*. 1977;34:189-194.
61. Samples JR, Janowsky DS, Pechnick R, Judd LL. Lethal effects of physostigmine plus lithium in rats. *Psychopharmacology*. 1977;52:307-309.
62. Judd LL, Hubbard B, Janowsky DS, Huey LY, Attewell PA. The effect of lithium carbonate on affect, mood, and personality of normal subjects. *Archives of General Psychiatry*. 1977;34:346-351.
63. Judd LL, Hubbard B, Janowsky DS, Huey LY, Takahashi KI. The effect of lithium carbonate on the cognitive functions of normal subjects. *Archives of General Psychiatry*. 1977;34:355-357.

64. Janowsky DS, Segal DS, Bloom F, Abrams A, Guillemin R. Lack of effect of naloxone on schizophrenic symptoms. *American Journal of Psychiatry*. 1977;134:926-927.
65. Janowsky DS, Segal DS, Abrams A, Bloom F, Guillemin R. Negative naloxone effects in schizophrenic patients. *Psychopharmacology*. 1977;53:295-298.
66. Judd LL, Hubbard B, Huey LY, Attewell PA, Janowsky DS, Takahashi KI. Lithium carbonate and ethanol induced "highs" in normal subjects. *Archives of General Psychiatry*. 1977;34:463-467.
67. Gash A, Karliner JS, Janowsky D. Effects of smoking marijuana on left ventricular performance and plasma norepinephrine: Studies in normal men. *Annals of Internal Medicine*. 1978;89:448-452.
68. Hawkins R, Kripke DF, Janowsky DS. Circadian rhythm of lithium toxicity in mice. *Psychopharmacology*. 1978;56:113-114.
69. Janowsky DS, Leichner P, Parker D, Judd L, Huey L, Clopton P. Methylphenidate and serum prolactin in man. *Psychopharmacology*. 1978;58:43-47.
70. Janowsky DS, Leichner P, Parker D, Judd LL, Huey L, Clopton P. The effect of methylphenidate on serum growth hormone. *Archives of General Psychiatry*. 1978;35:1384-1389.
71. Janowsky DS, Leichner P, Clopton P, Judd LL, Parker D, Huey L. Comparison of oral and intravenous methylphenidate. *Psychopharmacology*. 1978;59:75-78.
72. Miley DP, Abrams AA, Atkinson JH, Janowsky DS. Successful treatment of thalamic pain with apomorphine. *American Journal of Psychiatry*. 1978;135:1230-1232.
73. Abrams A, Braff D, Janowsky D, Hall S, Segal D. Unresponsiveness of catatonic symptoms to naloxone. *Pharmacopsychiatry*. 1978;11:177-179.
74. Janowsky D, Judd L, Huey L, Roitman N, Parker D, Segal D. Naloxone effects on manic symptoms and growth-hormone levels. *Lancet*. 1978;2:320 (letter).
75. Janowsky D, Judd L, Huey L, Roitman N, Parker D, Segal D. Negative naloxone effects on serum-prolactin. *Lancet*. 1978;2:637 (letter).
76. Huey LY, Zetin M, Janowsky DS, Judd LL. Adult minimal brain dysfunction and schizophrenia: A case report. *American Journal of Psychiatry*. 1978;135:1563-1565.
77. Kripke DF, Judd LL, Hubbard B, Janowsky DS, Huey LY. The effect of lithium carbonate on the circadian rhythm of sleep in normal human subjects. *Biological Psychiatry*. 1979;14:545-548.
78. Janowsky DS, Clopton PL, Leichner PP, Abrams AA, Judd LL, Pechnick R. Interpersonal effects of marijuana. *Archives of General Psychiatry*. 1979;36:781-785.
79. Clopton PL, Janowsky DS, Clopton JM, Judd LL, Huey L: Marijuana and the perception of affect. *Psychopharmacology*. 1979;61:203-206.
80. Nasrallah HA, Holley T, Janowsky DS. Opiate antagonism fails to reverse hypnotic-induced analgesia. *Lancet*. 1979;1:1355 (letter).
81. Risch SC, Huey LY, Janowsky DS. Plasma levels of tricyclic antidepressants and clinical efficacy: Review of the literature-Part I. *Journal of Clinical Psychiatry*. 1979;40:4-16.

82. Janowsky DS, Abrams AA, Groom GP, Judd LL, Cloptin P. Lithium administration antagonizes cholinergic behavioral effects in rodents. *Psychopharmacology*. 1979;63:147-159.
83. Janowsky DS, Risch C. Amphetamine psychosis and psychotic symptoms. *Psychopharmacology*. 1979;65:73-77.
84. Janowsky D, Judd L, Huey L, Roitman N, Parker D. Naloxone effects on serum growth hormone and prolactin in man. *Psychopharmacology*. 1979;65:95-97.
85. Pechnick R, Janowsky DS, Judd LL: Differential effects of methylphenidate and d-amphetamine on stereotyped behavior in the rat. *Psychopharmacology*. 1979;65:311-315.
86. Berryhill RE, Benumof JL, Janowsky DS. Morphine-induced hyperexcitability in man. *Anesthesiology*. 1979;50:65-66.
87. Janowsky D, Davis J, Dysken M, Killian G. Provocative pharmacological agents for psychiatric diagnosis: Methylphenidate, sodium amobarbital and physostigmine. *Neuro-Psychopharmacology*. 1979;489-495.
88. Risch SC, Huey LY, Janowsky DS. Plasma levels of tricyclic antidepressants and clinical efficacy: Review of the literature - Part II. *Journal of Clinical Psychiatry*. 1979;40:58-69.
89. Risch SC, Huey LY, Janowsky DS. Important information recently received. *Journal of Clinical Psychiatry*. 1979;40:113 (update).
90. Squire LR, Judd LL, Janowsky DS, Huey LY. Effects of lithium carbonate on memory and other cognitive functions. *American Journal of Psychiatry*. 1980;137:1042-1046.
91. Judd LL, Janowsky DS, Segal DS, Huey LY. Naloxone-induced behavioral and physiological effects in normal and manic subjects. *Archives of General Psychiatry*. 1980;37:583-586.
92. Huey LY, Janowsky DS, Judd LL, Roitman NA, Clopton PL, Segal D. The effects of naloxone on methylphenidate-induced mood and behavioral changes: A negative study. *Psychopharmacology*. 1980;67:125-130.
93. Risch C, Kripke D, Janowsky D. Flurazepam effects on methylphenidate-induced stereotyped behavior. *Psychopharmacology*. 1980;70:79-82.
94. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Murphy DL. Mood and behavioral effects of physostigmine on humans are accompanied by elevations of plasma b-endorphin and cortisol. *Science*. 1980;209:1545-1546.
95. Neborsky R, Janowsky D, Munson E, Depry D. Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol: Behavioral consideration. *Archives of General Psychiatry*. 1981;38:195-199.
96. Risch SC, Groom GP, Janowsky DS. Interfaces of psychopharmacology and cardiology - Part One. *Journal of Clinical Psychiatry*. 1981;42:23-34.
97. Risch SC, Groom GP, Janowsky DS. Interfaces of psychopharmacology and cardiology - Part Two. *Journal of Clinical Psychiatry*. 1981;42:47-59.
98. Judd LL, Janowsky DS, Segal DS, Parker DC, Huey LY. Behavioral effects of methadone in schizophrenic patients. *American Journal of Psychiatry*. 1981;138:243-245.

99. Risch SC, Cohen RM, Janowsky DS, Kalin NH, Sitaram N, Gillin JC, Murphy DL. Physostigmine induction of depressive symptomatology in normal human subjects. *Psychiatry Research*. 1981;4:89-94.
100. Janowsky EC, Risch C, Janowsky DS. Effects of anesthesia on patients taking psychotropic drugs. *Journal of Clinical Psychopharmacology*. 1981;1:14-20.
101. Gomez RL, Janowsky D, Zetin M, Huey L, Clopton PL. Adult psychiatric diagnosis and symptoms compatible with the hyperactive child syndrome: A retrospective study. *Journal of Clinical Psychiatry*. 1981;42:389-394.
102. Neborsky RJ, Janowsky DS. Early treatment response and predictive outcome. *American Journal of Psychiatry*. 1981;138:538 (letter)
103. Risch SC, Kalin NH, Janowsky DS, Huey LY. Indications and guidelines for plasma tricyclic antidepressant concentration monitoring. *Journal of Clinical Psychopharmacology*. 1981;1:59-63.
104. Kalin NH, Risch SC, Janowsky DS, Murphy DL. Use of the dexamethasone suppression test in clinical psychiatry. *Journal of Clinical Psychopharmacology*. 1981;1:64-69.
105. Braff DL, Silverton L, Saccuzzo DP, Janowsky DS. Impaired speed of visual information processing in marijuana intoxication. *American Journal of Psychiatry*. 1981;138:613-617.
106. Janowsky DS. Cholinergic hypersensitivity in patients with affective disorders. *The Western Journal of Medicine*. 1981;134:144-145 (letter).
107. Wetzel CD, Squire LR, Janowsky DS. Methylphenidate impairs learning and memory in normal adults. *Behavioral and Neural Biology*. 1981;31:413-424.
108. Risch SC, Kalin NH, Janowsky DS. Cholinergic challenges in affective illness: Behavioral and neuroendocrine correlates. *Journal of Clinical Psychopharmacology*. 1981;1:186-192.
109. Judd LL, Janowsky DS, Zettner A, Huey LY, Takahashi KI. Effects of naloxone-HCl on cortisol levels in patients with affective disorder and normal controls. *Psychiatry Research*. 1981;4:277-283.
110. Janowsky EC, Janowsky DS, Pechnick R. Local anesthetic toxicity. *Anesthesia and Analgesia*. 1981;60:455 (letter).
111. Judd LL, Janowsky DS, Segal DS, Huey LY. Naloxone-induced lethargy. *Archives of General Psychiatry*. 1981;38:845 (letter in reply).
112. Grodner S, Braff D, Janowsky D, Clopton P. Efficacy of Art/Movement Therapy in Elevating Mood. *Arts in Psychotherapy*. 1982;9:217-225.
113. Neborsky R, Janowsky D, Munson E, Hornbeck C, Depry D. Behavioral prediction of response to haloperidol: A test dose strategy. *Journal of Clinical Psychiatry*. 1982;43:157-158.
114. Wetzel CD, Janowsky DS, Clopton PL. Remote memory during marijuana intoxication. *Psychopharmacology*. 1982;76:278-281.

115. Judd LL, Parker DC, Janowsky DS, Segal DS, Risch SC, Huey LY. The effect of methadone on the behavioral and neuroendocrine responses of manic patients. *Psychiatry Research*. 1982;7:163-170.
116. Risch SC, Groom GP, Janowsky DS. The effects of psychotropic drugs on the cardiovascular system. *Journal of Clinical Psychiatry*. 1982;43:16-31.
117. Janowsky DS, Atkinson JH. Administrative democracy on the psychiatric ward: Nursing and psychiatric resident issues. *International Journal of Therapeutic Communities*. 1982;3:126-137.
118. Neborsky RJ, Janowsky DS, Perel JM. Red blood cell/plasma haloperidol ratios and antipsychotic efficacy. *Psychiatry Research*. 1982;6:123 (letter).
119. Judd LL, Risch SC, Parker DC, Janowsky DS, Segal DS, Huey LY. Blunted prolactin response: A neuroendocrine abnormality manifested by depressed patients. *Archives of General Psychiatry*. 1982;39:1413-1416.
120. Risch SC, Janowsky DS, Siever LJ, Judd LL, Rausch JL, Huey LY, Beckman KA, Cohen RM, Murphy DL. Correlated cholinergical-stimulated beta-endorphin and prolactin release in humans. *Peptides*. 1982;3:319-322.
121. Janowsky DS. Pseudodementia in the elderly: Differential diagnosis and treatment. *Journal of Clinical Psychiatry*. 1982;43:19-25.
122. Risch SC, Kalin NH, Janowsky DS, Cohen RM, Pickar D, Murphy DL. Co-release of ACTH and beta-endorphin immunoreactivity in human subjects in response to central cholinergic stimulation. *Science*. 1983;222:77.
123. Arnsten AFT, Segal DS, Neville JH, Hillyard SA, Janowsky DS, Judd LL, Bloom FE. Naloxone augments electrophysiological signs of selective attention in man. *Nature*. 1983;304:725-727.
124. Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K, LeWinter M. Ventricular arrhythmias possibly aggravated by trazodone. *American Journal of Psychiatry*. 1983;140:796-797.
125. Kripke DF, Risch SC, Janowsky D. Bright white light alleviates depression. *Psychiatry Research*. 1983;10:105-112.
126. Janowsky DS, Judd LL, Huey LY, Risch SC, Segal DS. Behavioral effects of opioid receptor antagonists in psychopathologic states. *Psychiatric Clinics of North America*. 1983;6:403-414.
127. Janowsky DS, Risch SC, Huey LY, Judd LL, Rausch JL. Hypothalamic-pituitary-adrenal regulation, neurotransmitters and affective disorders. *Peptides*. 1983;4:775-784.
128. Risch SC, Janowsky DS, Gillin JC. Muscarinic supersensitivity of anterior pituitary ACTH and B-endorphin release in major depressive illness. *Peptides*. 1983;4:789-792.
129. Janowsky DS, Curtis G, Zisook S, Kuhn K, Resovsky K, LeWinter M. Trazodone-aggravated ventricular arrhythmias. *Journal of Clinical Psychopharmacology*. 1983;3:372-376.
130. Judd LL, Risch SC, Segal DS, Janowsky DS, Huey LY. Behavioral and neuroendocrine effects of opioid receptor agonists in psychopathologic states. *Psychiatric Clinics of North America*. 1983;6:393-402.

131. Risch SC, Janowsky DS, Judd LL, Gillin JC, McClure SF. The role of endogenous opioid systems in neuroendocrine regulation. *Psychiatric Clinics of North America*. 1983;6:429-441.
132. Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D. Plasma/RBC ratios and improvement in acute psychotic symptoms. *Journal of Clinical Psychiatry*. 1984;45:10-13.
133. Risch SC, Janowsky DS, Lisansky J, Strassman RJ, Rausch JL, Gillin JC, Judd LL, Huey LY. Dexamethasone effects on self-rated mood in depressed inpatients. *American Journal of Psychiatry*. 1984;141:147-148.
134. Gruber LN, Janowsky DS, Mandell AJ, Risch SC, Huey LY. A psychoacoustic effect upon mood and its relation to affective instability. *Comprehensive Psychiatry*. 1984;25:106-112.
135. Janowsky DS, Risch SC. Cholinomimetic and anticholinergic drugs used to investigate an acetylcholine hypothesis of affective disorders and stress. *Drug Development Research*. 1984;4:125-142.
136. Kraft AM, Willner P, Gillin CG, Janowsky D, Neborsky R. Changes in thought content following sleep deprivation in depression. *Comprehensive Psychiatry*. 1984;25:283-289.
137. Janowsky DS, Kraft A, Clopton P, Huey L. Relationships of mood and interpersonal perceptions. *Comprehensive Psychiatry*. 1984;25:546-551.
138. Janowsky DS, Risch SC, Ziegler M, Kennedy B, Huey LY. A cholinomimetic model of motion sickness and space adaptation syndrome. *Aviation, Space, and Environmental Medicine*. 1984;55:692-696.
139. Kennedy B, Janowsky DS, Risch SC, Ziegler MG. Central cholinergic stimulation causes adrenal epinephrine release. *Journal of Clinical Investigations*. 1984;74:972-975.
140. Moss DE, Koob GF, McMaster SB, Janowsky DS. Comparative effects of tetrahydrocannabinol on psychostimulant-induced behaviors. *Pharmacology Biochemistry and Behavior*. 1984;21:641-644.
141. Arnsten AFT, Neville HJ, Hillyard SA, Janowsky DS, Segal DS. Naloxone increases electrophysiological measures of selective information processing in humans. *Journal of Neuroscience*. 1984;4:2912-2919.
142. Janowsky DS, Byerley B. Desipramine - An overview. *Journal of Clinical Psychiatry*. 1984;45:3-7.
143. Janowsky D, Drennan M, Berkowitz A, Turken A, Risch SC. Anticholinergic antagonism of cholinesterase inhibitor lethality. *Lancet*. 1984;2:747 (letter).
144. Janowsky DS, Risch SC. An acetylcholine hypothesis of stress modulation. *Integrative Psychiatry*. 1985;3:3-16.
145. Janowsky DS, Risch SC, Huey LY. Central cardiovascular effects of physostigmine in humans. *Hypertension*. 1985;7:140-145.
146. Rausch JL, Janowsky DS, Risch SC, Huey LY. Physostigmine effects on serotonin uptake in human blood platelets. *European Journal of Pharmacology*. 1985;109:91-96.

147. Janowsky DS, Risch SC, Huey LY, Kennedy B, Ziegler M. Effects of physostigmine on pulse, blood pressure, and serum epinephrine levels. *American Journal of Psychiatry*. 1985;142:738-740.
148. Dysken MW, Janowsky DS. Dose-related physostigmine-induced ventricular arrhythmia: Case report. *Journal of Clinical Psychiatry*. 1985;46:446-447.
149. Janowsky DS, Berkowitz A, Turken A, Risch SC. Antagonism of physostigmine induced lethality by a combination of scopolamine and methscopolamine. *Acta Pharmacologica et Toxicologica*. 1985;56:154-157.
150. Janowsky DS, Drennan M, Berkowitz A, Turken A, Risch SC. Comparative effects of scopolamine and atropine in preventing cholinesterase inhibitor induced lethality. *Military Medicine*. 1985;150:693-695.
151. Zisook S, Janowsky DS, Overall JE, Risch SC. The dexamethasone suppression test and unipolar/bipolar distinctions. *Journal of Clinical Psychiatry*. 1985;46:461-465.
152. Janowsky EC, Janowsky DS. What precautions should be taken if the patient on an MAOI is scheduled to undergo anesthesia? *Journal of Clinical Pharmacology*. 1985;5:128-129 (letter).
153. Kelsoe JR, Gillin JC, Janowsky DS, Brown JH, Risch SC, Lumkin B. Failure to confirm muscarinic receptors on skin fibroblasts. *New England Journal of Medicine*. 1985;312:861-862 (letter).
154. Janowsky DS, Rausch J. Biochemical hypotheses of premenstrual tension syndrome. *Psychological Medicine*. 1985;15:3-8 (editorial).
155. Atkinson JH, Kremer EF, Risch SC, Janowsky DS. Basal and post-dexamethasone cortisol and prolactin concentrations in depressed and non-depressed patients with chronic pain syndromes. *Pain*. 1986;25:23-34.
156. Janowsky DS, Risch SC, Kennedy B, Ziegler MG, Huey LY. Acute effects of physostigmine and neostigmine in man. *Military Medicine*. 1986;151:48-51.
157. Janowsky DS, Glick ID, Lash L, Mitnick L, Klein DF, Goodwin FK, Hanin I, Nemeroff C, Robins L. Psychobiology and psychopharmacology: Issues in clinical research training. *Journal of Clinical Psychopharmacology*. 1986;6:1-7.
158. Kelsoe JR, Gillin JC, Janowsky DS, Brown JH, Risch SC, Lumkin B. Specific [3H]-N-methyl scopolamine binding without cholinergic function in cultured adult skin fibroblasts. *Life Sciences*. 1986;38:1399-1408.
159. Risch SC, Janowsky DS, Mott MA, Gillin JC, Kalir HH, Huey LY, Ziegler M, Kennedy B, Turken A. Central and peripheral cholinesterase inhibition: Effects on anterior pituitary and sympathomimetic function. *Psychoneuroendocrinology*. 1986;11:221-230.
160. Overstreet DH, Booth RA, Dana R, Risch SC, Janowsky DS. Enhanced elevation of corticosterone following arecoline administration to rats selectively bred for increased cholinergic function. *Psychopharmacology (Berlin)*. 1986;88:129-130.
161. Janowsky DS, Risch SC, Kennedy B, Ziegler M, Huey L. Central muscarinic effects of physostigmine on mood, cardiovascular function, pituitary and adrenal neuroendocrine release. *Psychopharmacology (Berlin)*. 1986;89:150-154.

162. Rausch JL, Janowsky DS, Risch SC, Huey LY. A kinetic analysis and replication of decreased platelet serotonin uptake in depressed patients. *Psychiatry Research*. 1986;19:105-112.
163. Janowsky DS, Risch SC, Ziegler MG, Gillin JC, Huey L, Rausch J. Physostigmine-induced epinephrine release in patients with affective disorder. *American Journal of Psychiatry*. 1986;143:919-921.
164. Atkinson JH, Kremer EF, Risch SC, Janowsky DS. Neuroendocrine responses in psychiatric and pain patients with major depression. *Biological Psychiatry*. 1986;21:612-620.
165. Overstreet DH, Janowsky DS, Gillin JC, Shiromani PJ, Sutin EL. Stress-induced immobility in rats with cholinergic supersensitivity. *Biological Psychiatry*. 1986;21:657-664.
166. Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: Implication for cholinergic hypotheses of dementia. *Behavioral and Neural Biology*. 1986;45:196-211.
167. Janowsky D, Risch S, Ziegler M, Gillin JC. Antagonistic effects of scopolamine and atropine on the physostigmine response in man. *Military Medicine*. 1987;152:579-581.
168. Risch SC, Janowsky DS, Judd LL, Gillin JC, Mott MA, Rausch JL, Huey L. Measurement of ACTH and prolactin in the Dexamethasone Suppression Test. *Acta Psychiatrica Scandinavica*. 1987;76:535-540.
169. Wolfe J, Granholm E, Butters N, Saunders E, Janowsky D. Verbal memory deficits associated with major affective disorders: A comparison of unipolar and bipolar patients. *Journal of Affective Disorders*. 1987;13:83-92.
170. Kennedy B, Strassman RJ, Ziegler MG, Janowsky DS, Risch SC, Huey LY, Gillin JC. Cardiovascular, catecholamine and psychological responses to TRH in four types of affective disorder patients. *Hormone and Metabolic Research*. 1987;19:164-167.
171. Risch SC, Ehlers C, Janowsky DS, Judd L, Gillin JC, Dann R, McAdams LA. Human growth hormone releasing factor infusion effects on plasma growth hormone in affective disorder patients and normal controls. *Peptides*. 1988;9(suppl 1):45-48.
172. Darko DF, Lucas AH, Gillin JC, Risch SC, Golshan S, Hamburger RN, Silverman MB, Janowsky DS. Cellular immunity and the hypothalamic-pituitary axis in major affective disorder: A preliminary study. *Psychiatry Research*. 1988;25:1-9.
173. Risch SC, Golshan S, Rapaport MH, Dupont R, Outenreath R, Gillin JC, Janowsky DS. Neuroendocrine effects of intravenous ovine corticotropin-releasing factor in affective disorder patients and normal controls. *Biological Psychiatry*. 1988;23:755-758.
174. Darko DF, Lucas AH, Gillin JC, Risch SC, Golshan S, Hamburger RN, Silverman MB, Janowsky DS. Age, cellular immunity and the HP axis in major depression. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 1988;12:713-720.
175. Zisook S, Janowsky D, Smith C. Fezolamine fumarate, a new antidepressant. *Current Therapeutic Research*. 1988;43:1183-1189.
176. Overstreet DH, Russell RW, Crocker AD, Gillin JC, Janowsky DS. Genetic and pharmacological models of cholinergic supersensitivity and affective disorders. *Experientia*. 1988;44:465-472.

177. Rausch JL, Janowsky DS, Golshan S, Kuhn K, Risch SC. Atenolol treatment of late luteal phase dysphoric disorder. *Journal of Affective Disorders*. 1988;15:141-147.
178. Byerley WF, Risch SC, Gillin JC, Janowsky DS, Parker D, Rossman LG, Kripke DF. Biological effect of bright light. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 1989;13:683-686.
179. Gillin JC, Kripke DF, Janowsky DS, Risch SC. Effects of brief naps on mood and sleep in sleep-deprived depressed patients. *Psychiatry Research*. 1989;27:253-265.
180. Overstreet DH, Janowsky DS, Rezvani AH. Alcoholism and depressive disorders: Is cholinergic sensitivity a biological marker? *Alcohol and Alcoholism*. 1989;24:253-255.
181. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky DS. Blunted growth hormone response to peripheral infusion of human growth hormone-releasing factor in patients with panic disorder. *American Journal of Psychiatry*. 1989;146:92-95.
182. Campbell SS, Gillin JC, Kripke DF, Janowsky DS, Risch SC. Lithium delays circadian phase of temperature and REM sleep in a bipolar depressive: A case report. *Psychiatry Research*. 1989;27:23-29.
183. Janowsky DS, Risch SC, Irwin M, Schuckit MA. Behavioral hyporeactivity to physostigmine in detoxified primary alcoholics. *American Journal of Psychiatry*. 1989;146:538-539.
184. Conant J, Engler R, Janowsky DS, Maisel A, Gilpin E, LeWinter M. Central nervous system side effects of beta-adrenergic blocking agents with high and low lipid solubility. *Journal of Cardiovascular Pharmacology*. 1989;13:656-661.
185. Morrisett RA, Rezvani AH, Overstreet D, Janowsky DS, Wilson WA, Swartzwelder HS. MK-801 potently inhibits alcohol withdrawal seizures in rats. *European Journal of Pharmacology*. 1990;176:103-105.
186. Overstreet DH, Janowsky DS, Rezvani AH. Alcoholism and depressive disorders: Is cholinergic sensitivity a biological marker? *Alcohol and Alcoholism*. 1989;24:253-255.
187. Janowsky DS, Overstreet DH. Cholinergic dysfunction in depression. *Pharmacology and Toxicology*. 1990;66(suppl 3):100-111.
188. Rezvani AH, Overstreet DH, Janowsky DS. Reduction in ethanol preference following injection of centrally and peripherally acting antimuscarinic agents. *Alcohol and Alcoholism*. 1990;25:3-7.
189. Rezvani AH, Mack CM, De Lacy PA, Janowsky DS. Verapamil effects on physiological and behavioral responses to ethanol in the rat. *Alcohol and Alcoholism*. 1990;25:51-58.
190. Overstreet DH, Rezvani AH, Janowsky DS. Increased hypothermic responses to ethanol in rats selectively bred for cholinergic supersensitivity. *Alcohol and Alcoholism*. 1990;25:59-65.
191. Berkowitz A, Sutton L, Janowsky DS, Gillin JC. Pilocarpine, an orally active muscarinic cholinergic agonist, induces REM sleep and reduces delta sleep in normal volunteers. *Psychiatry Research*. 1990;33:113-119.
192. Rezvani A, Overstreet D, Janowsky D. Genetic serotonin deficiency and alcohol preference in the Fawn Hooded rats. *Alcohol and Alcoholism*. 1990;25:573-575.

193. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS. Effect of verapamil on submissive behavior in genetically bred hypercholinergic rats in a water competition task. *European Journal of Pharmacology*. 1990;187:507-511.
194. Overstreet DH, Rezvani AH, Janowsky DS. Impaired active avoidance responding in rats selectively bred for increased cholinergic function. *Physiology and Behavior*. 1990;47:787-788.
195. Overstreet DH, Dilsaver SC, Janowsky DS, Rezvani AH. Effects of bright light on responsiveness to a muscarinic agonist in rats selectively bred for endogenously increased cholinergic function. *Psychiatry Research*. 1990;33:139-150.
196. Overstreet DH, Dilsaver SC, Rezvani AH, Janowsky DS. Selective antagonistic effects of exposure to bright light on the hypothermic action of ethanol. *Alcohol and Alcoholism*. 1990;25:661-665.
197. Pucilowski O, Eichelman B, Overstreet DH, Rezvani AH, Janowsky DS. Enhanced affective aggression in genetically bred hypercholinergic rats. *Neuropsychobiology*. 1990-1991;24:37-41.
198. Rezvani AH, Janowsky DS. Decreased alcohol consumption by Verapamil in alcohol preferring rats. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. 1990;14:623-631.
199. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS. Effects of calcium channel inhibitors on the hypothermic response to oxotremorine in normo and hypercholinergic rats. *Journal of Pharmacy and Pharmacology*. 1991;43:436-439.
200. Rapaport MH, Risch SC, Gillin JC, Golshan S, Janowsky D. The effects of physostigmine infusion on patients with panic disorder. *Biological Psychiatry*. 1991;29:658-664.
201. Owens MJ, Overstreet DH, Knight DL, Rezvani AH, Ritchie JC, Bissette G, Janowsky DS, Nemeroff CB. Alterations in the hypothalamic-pituitary-adrenal axis in a proposed animal model of depression with genetic muscarinic supersensitivity. *Neuropsychopharmacology*. 1991;4:87-93.
202. Pucilowski O, Danysz W, Overstreet DH, Rezvani AH, Eichelman B, Janowsky DS. Decreased hyperthermic effect of MK-801 in selectively bred hypercholinergic rats. *Brain Research Bulletin*. 1991;26:621-625.
203. Gillin JC, Sutton L, Ruiz C, Darko D, Golshan S, Risch SC, Janowsky D. The effects of scopolamine on sleep and mood in depressed patients with a history of alcoholism and a normal comparison group. *Biological Psychiatry*. 1991;30:157-169.
204. Rezvani AH, Grady DR, Janowsky DS. Effect of calcium-channel blockers on alcohol consumption in alcohol-drinking monkeys. *Alcohol and Alcoholism*. 1991;26:161-167.
205. Rezvani AH, Overstreet DH, Janowsky DS. Drug-induced reductions in ethanol intake in alcohol preferring and Fawn-Hooded rats. *Alcohol and Alcoholism*. 1991;Suppl 1:433-437.
206. Gillin JC, Sutton L, Ruiz C, Kelsoe J, Dupont RM, Darko D, Risch SC, Golshan S, Janowsky D. The cholinergic rapid eye movement induction test with arecoline in depression. *Archives of General Psychiatry*. 1991;48:264-270.
207. Rezvani AH, Garbutt JC, Shimoda K, Garges PL, Janowsky DS, Mason GA. Attenuation of alcohol preference in alcohol preferring rats by a novel TRH analogue, TA-0910. *Alcoholism: Clinical and Experimental Research*. 1992;16:326-330.

208. Pucilowski O, Rezvani AH, Janowsky DS. Suppression of alcohol and saccharin preference in rats by a novel Ca²⁺ channel inhibitor, Goe 5438. *Psychopharmacology (Berlin)*. 1992;107:447-452.
209. Overstreet DH, Rezvani AH, Janowsky DS. Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism. *Biological Psychiatry*. 1992;31:919-936.
210. Ayensu WK, Rezvani AH, Overstreet DH, Pucilowski O, Janowsky DS. Ethanol and complement hemolytic activity of selectively bred hypercholinergic rats. *Alcohol and Alcoholism*. 1992;27:47-54.
211. Keenan PA, Stern RA, Janowsky DS, Pedersen CA. Psychological aspects of premenstrual syndrome. I: Cognition and memory. *Psychoneuroendocrinology*. 1992;17:179-187.
212. Overstreet DH, Rezvani AH, Janowsky DS. Maudsley reactive and nonreactive rats differ only in some tasks reflecting emotionality. *Physiology and Behavior*. 1992;52:149-152.
213. Pucilowski O, Overstreet DH, Rezvani AH, Janowsky DS. Chronic mild stress-induced anhedonia: Greater effect in a genetic rat model of depression. *Physiology and Behavior*. 1993;54:1215-1220.
214. Overstreet DH, Kampov-Polevoy AB, Rezvani AH, Murrelle L, Halikas J, Janowsky DS. Saccharin intake predicts ethanol intake in genetically heterogeneous rats as well as different rat strains. *Alcoholism: Clinical Experimental Research*. 1993;17:366-369.
215. Rezvani AH, Grady D, Pucilowski O, Janowsky DS. Suppression of alcohol intake in alcohol-preferring rats by the Ca²⁺ channel antagonist Nimodipine. *Drugs in Development. Ca²⁺ Antagonists in CNS*. 1993;2:143-151.
216. Pucilowski O, Garges PL, Rezvani AH, Hutheson S, Janowsky DS. Verapamil suppresses d-amphetamine-induced place preference conditioning. *European Journal of Pharmacology*. 1993;240:89-92.
217. Glick ID, Janowsky DS, Salzman C, Shader RI. A proposal for a model psychopharmacology curriculum for psychiatric residents. *Neuropsychopharmacology*. 1993;8:1-5.
218. Sdao-Jarvie K, Berolzheimer N, Rounds J, Janowsky DS. Substance abuse screening of hospitalized patients and its effect on physician behavior. *Substance Abuse*. 1993;14:28-34.
219. Rezvani AN, Pucilowski O, Grady DR, Janowsky D, O'Brien RA. Reduction of spontaneous alcohol drinking and physical withdrawal by Levemopamil, a novel Ca²⁺ channel antagonist, in rats. *Pharmacology Biochemistry and Behavior*. 1993;46:365-371.
220. Overstreet DH, Rezvani AH, Pucilowski O, Gause L, Janowsky DS. Rapid selection for serotonin-1A sensitivity in rats. *Psychiatric Genetics*. 1994;4:57-62.
221. Overstreet DH, Janowsky DS, Pucilowski O, Rezvani AH. Swim test immobility co-segregates with serotonergic but not cholinergic sensitivity in cross-breeds of Flinders Line rats. *Psychiatric Genetics*. 1994;4:101-107.
222. Pucilowski O, Rezvani AH, Overstreet DH, Janowsky DS. Calcium channel inhibitors attenuate consumption of ethanol, sucrose and saccharin solutions in rats. *Behavioral Pharmacology*. 1994;5:494-501.

223. Janowsky DS, Overstreet DH, Nurnberger,JI. Is cholinergic sensitivity a genetic marker for the affective disorders? *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 1994, 54:335-344.
224. Ayensu WK, Pucilowski O, Mason GA, Overstreet DH, Rezvani AH, Janowsky DS. Effects of chronic mild stress on serum complement activity, saccharin preference, and corticosterone levels in Flinders Lines of Rats. *Physiology & Behavior*, 1995, 57:165-169.
225. Kampov-Polevoi AB, Overstreet DH, Rezvani AH, Janowsky DS. Saccharin-induced increases in daily fluid intake as a predictor of voluntary alcohol intake in alcohol-preferring rats. *Physiology & Behavior*, 1995, 57:791-795.
226. Overstreet DH, Pucilowski O, Rezvani AH, Janowsky DS. Administration of antidepressants, diazepam and psychomotor stimulants further confirms the utility of Flinders Sensitive Line rats as an animal model of depression. *Psychopharmacology*, 1995, 121:27-37.
227. Overstreet DH, Lee Y-W, Rezvani AH, Criswell HE, Janowsky DS. Suppression of alcohol intake following injection of the Chinese herbal medicine, XJL(NPI-028). *Alcoholism: Clinical and Experimental Research*, 20(2)221-227, 1996.
228. Kampov-Polevoi AB, Overstreet DH, Rezvani AH, Janowsky DS. Suppression of ethanol intake in alcohol-preferring rats by prior voluntary saccharin consumption. *Psychopharmacol. Biochem. Behavior*, 1995, 52:59-64.
229. Overstreet DH, Rezvani AH, Pucilowski O, Janowsky DS. 5-HT Receptors: Implications for the Neuropharmacology of Alcohol and alcoholism. *Alcohol & Alcoholism (Suppl)*, 1995, 2:207-212.
230. Overstreet DH, Rezvani AH, Knapp DJ, Crews FT, Janowsky DS. Further selection of rat lines differing in 5-HT-1A receptor Sensitivity: behavioral and functional correlates. *Psychiatric Genetics*, 1996, 6:107-117.
231. Overstreet DH, Miller CM, Janowsky DS, Russell RW. A potential animal model of multiple chemical sensitivity with cholinergic supersensitivity. *Toxicology*, 1996, 111:119-134.
232. Kampov-Polevoi A, Garbutt JC, Janowsky D. Evidence of preference for high concentration sucrose solution in alcoholic men. *Am J Psychiatry*, 1997, 154(2) 269-270
234. Kampov-Polevoi AB, Garbutt JC, Davis CE, Janowsky DS. Preference for high sugar concentrations and Tridimensional Personality Questionnaire scores in alcoholic and non-alcoholic men. *Alcohol Clin Exp Res*, 1998, 22(3) 610-614.
235. Overstreet DH, Daws LC, Schiller GD, Orbach J, Janowsky DS. Cholinergic-serotonergic interactions in hypothermia: Implications for rat models of depression. *Pharmacol Biochem Behav*, 1998, 59(4) 777-785.
236. Janowsky DS, Hong L, Morter S, Howe L. Underlying personality differences between alcohol/substance disorder patients with and without an affective disorder. *Alcohol and Alcoholism* 34(3) 370-377, 1999.

237. Janowsky DS, Boone A, Morter S, Howe L. Personality and alcohol/substance disorder patient relapse and attendance at self help group meetings. *Alcohol and Alcoholism* 34(3) 359-369, 1999.
238. Kampov-Polevoi AB, Garbutt JC, Janowsky DS. Association between preference for sweets and excessive alcohol intake: A review of animal and human studies. *Alcohol and Alcoholism* May/June, 1999.
239. Janowsky DS. Introduction to personality – biological interactions in alcoholism: “The Markku Linnoila Memorial Symposium. *Alcohol and Alcoholism* 34(3) 357-358, 1999.
240. Janowsky DS, Morter S, Hong L, Howe L. Myers Briggs Type Indicator and Tridimensional Personality Questionnaire differences between Bipolar and Major Depressive Disorder patients. *Bipolar Disorders*, 1(2):98-108, 1999.
241. Tizabi Y, Overstreet DH, Louis VA, Clark E Jr., Janowsky DS, Kling MA. Antidepressant effects of nicotine in an animal model of depression. *Psychopharmacology* (Berl) 142(2):193-199, 1999.
242. Janowsky DS. New treatments of bipolar disorder. *Current Psychiatry Reports* 1(2):111-113, 1999.
243. Rezvani AH, Overstreet DH, Mason GA, Janowsky DS, Hamed M, Clark E, Yang Y. Combination pharmacotherapy: A mixture of small doses of naltrexone, fluoxetine and a thyrotropin-releasing hormone analogue reduces alcohol intake in three strains of alcohol preferring rats. *Alcohol and Alcoholism*, 2000, 35(1) 76-83.
244. Janowsky DS, Morter S, Tancer M: Myers Briggs Type Indicator personality profiles and social phobia. *Depression and Anxiety*, 11:121-125. 2000.
245. Alpert M, Angrist B, Clayton PJ, Conners, CK, Endicott J, Janowsky DS, McNair DM, Ray, O. The Department of Defense Psychopharmacology Demonstration Project. *ACNP Bulletin* 7(3):1-47. 2000.
246. Glick ID, Janowsky DS, Zisook S, Lydiard RB, Oesterheld JR, Ward NG, Ellison SJ, Halper J, Doraiswamy PM, Preven DW, Ross P, Klein DF. How should we teach psychopharmacology residents? Results of the initial experience with the ASCP Model Curriculum. *Acad Psychiatry* 25:90-97; 2001.
247. Glick ID, Janowsky D, Zisook S. On using the ASCP model curriculum for psychopharmacology: Comments and an update. *Academic Psychiatry* 25(4):237-238, 2001.
248. Janowsky DS. Clinical trials report. *Current Psychiatry Reports* 3(6):439-443, 2001.
249. Janowsky DS. Introversion and extroversion: implications for depression and suicidality. *Current Psychiatry Reports* 3(6):444-450, 2001.
250. Janowsky, DS, Fawcett J, Meszaros, K, Verheul, R. Core heritable personality characteristics and relapse in alcoholics. *Alcohol Clin Exp Res* 25(5):94S-98S, 2001.
251. Janowsky DS, Morter S, Hong L: The relationship of Myers Briggs Type Indicator personality characteristics to suicidality in affective disorder patients. *J Psychiatr Res*, 36(1): 33-39, 2002.
252. Janowsky, DS, Hong L, Morter S, Howe L. Myers Briggs Type Indicator personality characteristics in unipolar depressed patients. *World J Biol Psychiatry* 3:207-215, 2002.

253. Janowsky DS, Rausch, JL, Davis JM. Historical studies of premenstrual tension up to 30 years ago: Implications for future research. *Curr Psychiatry Rep* 4(6):411-418, 2002.
254. Janowsky DS. Central anticholinergics to treat nerve agent poisoning. *Lancet* 359(9302):265-266, 2002.
255. Janowsky DS, Barnhill J, Davis JM. Olanzapine treatment of self-injurious, aggressive and disruptive behavior in institutionalized adults with intellectual disability. *J Clinical Psychiatry*, 64(10):1258-1265, 2003.
256. Janowsky DS, Pucilowski O, Buyinza M. Preference for higher sucrose concentrations in cocaine abusing/dependent patients. *J Psychiatr Res* 37(1):35-31, 2003.
257. Janowsky DS, Kraus JE, Barnhill LJ, Elamir B, Davis JM. Effects of topiramate on aggressive, self-injurious, and disruptive/destructive behaviors in the intellectually disabled. An open-label retrospective study. *J of Clinical Psychopharmacology*, 23(5):500-504, 2003.
258. Janowsky DS. Depression and dysphoria effects on the interpersonal perception of negative and positive moods and caring relationships: Effects of antidepressants, amphetamine, and methylphenidate. *Current Psychiatry Reports* 5:451-459, 2003.
259. Overstreet DH, Daws LC, Yadid G, Friedman E, Mathe AA, Janowsky DS. Comment on preclinical models: Status of basic research in depression. *Biol Psych* 53(3):268-270, 2003.
260. Janowsky DS, Overstreet D. Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study. *Pharmacology Biochemistry and Behavior* 77(2):337-343, 2004.
261. Janowsky DS. Issues of functionality in bipolar disorders. *Current Psychiatry Reports* 6:449-450, 2004.
262. Janowsky DS, Shetty M, Barnhill J, Elamir B, Davis JM. Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective open-label, naturalistic trial. *Int J Neuropsychopharmacology* 8(1):37-48, 2005.
263. Janowsky DS, Barnhill LJ, Shetty M, Davis JM. Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults. *J Clin Psychopharmacology* 25(1):1-7, 2005.
264. Janowsky DS. Current issues in the treatment of bipolar disorder patients. *Current Psychiatry Reports* 7(6):485-486, 2005.
265. Janowsky DS, Davis JM. Diagnosis and treatment of depression in patients with mental retardation. *Current Psychiatry Reports* 7(6):421-428, 2005.
266. Janowsky DS, Davis JM, Overstreet DH. Anticholinesterase (DFP) Toxicity antagonism by chronic donepezil: A potential nerve agent treatment. *Pharmacol Biochem Behav* 81(4):917-922, 2005.
267. Janowsky DS, Barnhill LJ, Khalid AS, Davis JM. Relapse of Aggressive-disruptive behavior in the mentally retarded following antipsychotic drug withdrawal predicts psychotropic drug use a decade later. *J Clin Psychiatry* 67:1272-1277, 2006.
268. Janowsky DS. Recent depression updates: Relevant presentations. *Current Psychiatry Reports* 8(6):470-472, 2006.

269. Janowsky DS. Clinical Trials Report – Scopolamine as an antidepressant agent: theoretical and treatment considerations *Current Psychiatry Reports*. 9(6):447-448, 2007.
270. Janowsky DS, Barnhill LJ, Khalid, Abdul, Davis JM. Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. *Journal Clinical Psychopharmacology* 28(4):401-405, 2008.
271. Janowsky DS, Bipolar disorder-relevant abstracts of posters from the 2008 CINP congress. *Current Psychiatric Reports* 10 (6): 525-527, 2008.
272. Janowsky DS, Davis JM. Antipsychotic properties of muscarinic drugs *Amer J Psychiatry* 166 (1): 110, 2009.
273. Janowsky DS, Soares J, Hatch JP, Junta-Soares G, Hu Q, Davis JM. Lithium effect on renal glomerular function in individuals with intellectual disability. *J Clin Psychopharmacology* 29 (3): 296-299, 2009.
274. Janowsky DS. Bipolar disorder—and major depression-relevant abstracts from the 2009 9th world congress of biological psychiatry meeting. *Current Psychiatry Reports* 11 (6) 509-511, 2009.
275. Janowsky DS, Buneviciute J, Hu Q, Davis J. Lithium induced renal insufficiency- a longitudinal study of creatinine increases. *J Clin Psychopharmacology*, 31 (6) 769-773, 2011.
276. Janowsky DS, Buneviciute J, Hu Q, Davis J. Minimally effective doses of risperidone and olanzapine on aggressive behavior in intellectually disabled adults. *J Clin Psychopharmacology*, 31 (2) 238-240, 2011.
277. Janowsky DS. Serendipity strikes again: scopolamine as an antidepressant agent in bipolar depressed patients. *Current Psychiatry Reports*, 31 (6) 443-445, 2011.
278. Van Enkhuizen, Janowsky DS, Olieier B, Minassian A, Perry W, Young JW, Geyer, MA. The catecholaminergic-cholinergic balance hypothesis of bipolar disorder revisited, *European Journal of Pharmacology*, 2014.

B. Non-Refereed Journals

1. Gorney R, Janowsky DS, Kelley B. The curse - Vicissitudes and variations of the female fertility cycle. *Proceedings of the First International Congress of the Academy of Psychosomatic Medicine*, 1966:91-93.
2. Curry SH, Davis JM, Janowsky DS, Marshall JHL. Interpatient variation in physiological availability of chlorpromazine as a complicating factor in correlation studies of drug metabolism and clinical effect. *Proceedings of the Sixth International Congress of the C.I.N.P.*, 1969:72-76.
3. Fann WE, Oates JA, Janowsky DS, Davis JM. The effects of lithium and iprindole on adrenergic function in man. *Psychopharmacology Bulletin*. 1972;8:32.
4. Davis JM, Janowsky DS, El-Yousef MK. The use of lithium in clinical psychiatry. *Psychiatric Annals*. 1973;3:78-99.

5. Janowsky DS, Sekerke HJ, Davis JM. Differential affects of amantadine on pseudoparkinsonism and tardive dyskinesia. *Psychopharmacology Bulletin*. 1973;9:37-38.
6. Davis JM, Sekerke HJ, Janowsky DS. Drug interactions involving drugs of abuse. *Drugs of America, Problems in Perspective*, Vol. 1, 181-208, U.S. Govt. Printing Office, 1973.
7. Davis JM, Carrol B, Janowsky DS. Overdoses of psychotropic drugs; Parts I, II, and III. *Psychiatric Annals*. 1973;3:6-11.
8. Janowsky DS, El-Yousef MK, Davis JM. Effects of intravenous d-amphetamine, l-amphetamine and methylphenidate in schizophrenics. *Psychopharmacology Bulletin*. 1974;10:15-24.
9. Janowsky DS, Davis JM, Huey L, Judd LL. Methylphenidate and Physostigmine as Diagnostic Tools. Presented at the Annual ACNP Meeting, Puerto Rico, 1977, *Psychopharmacology Bulletin*. 1978;14:83-84.
10. Janowsky DS, Davis JM, Huey LY, Judd LL. Adrenergic and cholinergic drugs as episode and vulnerability markers of affective disorders and schizophrenia. *Psychopharmacology Bulletin*. 1979;15:33-34.
11. Janowsky DS, Risch SC, Parker D, Huey LY, Judd LL. Increased vulnerability to cholinergic stimulation in affective disorder patients. *Psychopharmacology Bulletin*. 1980;16:29-31.
12. Janowsky DS, Neborsky RJ. Hypothesized common mechanism in the psychotherapy and psychopharmacology of depression. *Psychiatric Annals*. 1980;10(Suppl):S3-S8.
13. Neborsky RJ, Janowsky DS, Fann WE. Psychopharmacologic and psychotherapeutic interventions: An integrated treatment approach to depression. *Psychiatric Annals*. 1980;10(suppl):S16-S27.
14. Huey LY, Janowsky DS, Judd LL, Abrams A, Clopton PL. Effects of lithium carbonate on methylphenidate-induced mood, behavior and cognitive processes. *Psychopharmacology Bulletin*. 1981;73:161-164.
15. Janowsky DS, Risch SC, Judd LL, Huey LY, Parer DC. Cholinergic supersensitivity in affect disorder patients: Behavioral and neuroendocrine observations. *Psychopharmacology Bulletin*. 1981;17:129-132.
16. Risch SC, Janowsky DS, Kalin NH, Cohen RM, Murphy DL. Cholinergic-endogenous opioid mechanisms in mood and cognition in man. *Psychopharmacology Bulletin*. 1981;17:132-137.
17. Risch SC, Janowsky DS. Trazodone. *Psychiatric Annals*. 1981;11:47-55.
18. Janowsky DS, Clopton PL, Huey LY, Judd LL. Effects of methylphenidate on interpersonal perceptions. *Psychopharmacology Bulletin*. 1981;17:183-186.
19. Janowsky DS. Management of depression in the elderly. *Journal of Family Practice Recertification*. 1982;4(suppl):37-48.
20. Judd LL, Risch SC, Parker DC, Janowsky DS, Segal DS, Huey LY. The effect of a methadone challenge on the prolactin and growth hormone responses of psychiatric patients and normal controls. *Psychopharmacology Bulletin*. 1982;18:204-207.

21. Risch SC, Janowsky DS, Judd LL, Huey LY. Elevated plasma B-endorphin concentrations in depression and cholinergically supersensitive release mechanisms. *Psychopharmacology Bulletin*. 1982;18:211-216.
22. Neborsky R, Janowsky D, Perel J, Munson E, Depry D. Haloperidol plasma/red blood cell ratios and clinical efficacy. *Psychopharmacology Bulletin*. 1982;18:17-20.
23. Risch SC, Janowsky DS, Siever LJ, Judd LL, Rausch JL, Huey LY, Beckman KA, Cohen RM, Murphy DL. Cholinomimetic induced co-release of prolactin and beta-endorphin in man. *Psychopharmacology Bulletin*. 1982;18:21-25.
24. Rausch JL, Janowsky DS, Risch SC, Judd LL, Huey LY. Hormonal and neurotransmitter hypotheses of premenstrual tension. *Psychopharmacology Bulletin*. 1982;18:25-34.
25. Risch SC, Janowsky DS, Gillin JC, Rausch JL, Loevinger BL, Huey LY. Muscarinic supersensitivity of anterior pituitary ACTH release in major depressive illness, adrenal cortical dissociation. *Psychopharmacology Bulletin*. 1983;19:343-346.
26. Judd LL, Risch SC, Janowsky DS, Segal DS, Huey LY. Methadone and metoclopramide may differentially effect prolactin secretion in depressed patients. *Psychopharmacology Bulletin*. 1983;19:482-485.
27. Kripke DF, Risch SC, Janowsky DS. Lighting up depression. *Psychopharmacology Bulletin*. 1983;19:526-530.
28. Groom G, Janowsky DS, Risch SC. Physostigmine down-regulation of beta adrenergic receptors. *Psychopharmacology Bulletin*. 1983;19:670-675.
29. Janowsky DS, Risch SC, Huey L, Judd L, Rausch J. Central physostigmine-induced cardiovascular and behavioral changes: Toward an acetylcholine hypothesis of stress. *Psychopharmacology Bulletin*. 1983;19:675-681.
30. Rausch JL, Janowsky DS, Risch SC, Huey LY, Judd LL. Cholinesterase inhibition in vitro and platelet serotonin uptake in depression. *Psychopharmacology Bulletin*. 1983;19:681-684.
31. Rausch JL, Janowsky DS, Risch SC, Clopton P, Huey LY, Judd LL. A platelet model for acetylcholine-serotonin interactions in the neuroendocrine activity of depressed mood. *Psychopharmacology Bulletin*. 1983;19:486-489.
32. Risch SC, Siever LJ, Gillin JC, Janowsky DS, Sitaram N, Weker J, Cohen RM, Murphy DL. Differential mood effects of arecoline in depressed patients and normal volunteers. *Psychopharmacology Bulletin*. 1983;19:696-698.
33. Huey LY, Janowsky DS, Judd L, Whitehall W, Zetin M, Risch SC, Loevinger B. Effects of methylphenidate in adult psychiatric inpatients: A preliminary report. *Psychopharmacology Bulletin*. 1984;20:10-17.
34. Janowsky DS, Risch SC. Adrenergic - cholinergic balance and affective disorders: A review of clinical evidence and therapeutic implications. *The Psychiatric Hospital*. 1984;15:163-171.
35. Atkinson JH, Kremer EF, Risch SC, Janowsky DS. Cortisol and prolactin responses to dexamethasone in major depression, chronic pain, and chronic pain with major depression. *Psychopharmacology Bulletin*. 1985;21:690-693.

36. Risch SC, Janowsky DS. Possible cholinergic mechanisms in space adaptation syndrome-behavioral and neuroendocrine correlates. *National Aeronautics and Space Administration, Life Sciences Medical Directorate*, 33-40, 1985.
37. Risch SC, Janowsky DS, Judd LL, Gillin JC, Mott M, Rausch JL, Huey LY. Multiendocrine assessment in the dexamethasone suppression test. *Psychopharmacology Bulletin*. 1986;22:913-916.
38. Gillin JC, Kelsoe JR, Kaufman CA, Kleinman JE, Risch SC, Janowsky DS. Muscarinic receptor density in skin fibroblasts and autopsied brain tissue in affective disorder. *Annals of The New York Academy of Sciences*. 1988;487:143-149.
39. Haggerty JJ, Golden RN, Evans DL, Janowsky DS. Differential diagnosis of pseudodementia in the elderly. *Geriatrics*. 1988;43:61-69,72,74.
40. Risch SC, Groom GP, Janowsky DS. Guidelines for the Use of Antidepressant, Antipsychotic and Sedative Hypnotic Medications in Patients with Cardiovascular Disease. *Quality of Life and Cardiovascular Care*. 1988;44-53.
41. Caldecott-Hazard S, Morgan D, DeLeon-Jones F, Overstreet DH, Janowsky D. Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories. *Synapse*. 1991;9:251-301.

C. Contributions to Text Books (Chapters and Books)

2. Janowsky DS, El-Yousef MK, Davis JM. The elicitation of psychotic symptomatology by methylphenidate. In: Cole J, ed. *Drugs and Psychopathology*. Baltimore, MD: Johns Hopkins University Press; 1973.
3. Davis JM, Janowsky DS, El-Yousef K. Pharmacology - The biology of lithium. In: Gershon S, Shopsin B, eds. *Lithium: Its Role in Psychiatric Research*. New York: Plenum Publishing Company; 1973.
4. Fann WE, Davis JM, Janowsky DS, Oates JA. Amine uptake in the pharmacology of affective disorders. In: Gershon S, Bunney W, eds. *Biogenic Amines in Psychiatry*. New York: Plenum Publishing Company; 1973.
5. Davis JM, Janowsky DS. Catecholamines and psychosis. In: Friedhoff A ed. *Catecholamines and Behavior*. New York: Plenum Press; 1973.
6. Davis JM, Janowsky DS, Sekerke HJ, Manier H, El-Yousef MK. The pharmacokinetics of butaperazine in serum. In: Forrest, Carr, Usdin, eds. *Phenothiazines and Structurally Related Compounds*. New York: Raven Press; 433-443,1973.
7. Janowsky DS, El-Yousef MK, Davis JM. Side effects associated with psychotropic drugs. In: Fann WE, Maddox GL, eds. *Drug Issues in Geropsychiatry*. Baltimore, MD: Williams & Wilkins; 28, 1974.
8. Janowsky DS, Sternbach RA. The Patient with Pain. Chapter 5, 99-116.
9. Janowsky DS, Davis JM. Dopamine, psychomotor stimulants, and schizophrenia: Effects of methylphenidate and the stereoisomers of amphetamine in schizophrenics. In: Usdin E, ed. *Neuropsychopharmacology of Monoamines and Their Regulatory Enzymes*. New York: Raven Press; 1974:317-323.

10. Davis JM, Janowsky D. Cholinergic and adrenergic balance in mania and schizophrenia. In: Domino EF, Davis JM, eds. *Neurotransmitter Balances Regulating Behavior*. Ann Arbor, Michigan; 1975:135-148.
 11. Shopsin B, Janowsky D, Davis J, Gershon S. Rebound phenomena in manic patients following physostigmine: Towards an understanding of the aminergic mechanisms underlying affective disorders. In: Domino EF, Davis JM, eds. *Neurotransmitter Balances Regulating Behavior*. Ann Arbor, MI; 1975:149-158.
 12. Davis JM, Janowsky D. Clinical Pharmacological Strategies. In: Mendels V, ed. *The Psychobiology of Depression*. Spectrum Publications, Inc; 1975:133-142.
 13. Sternbach RA, Janowsky DS, Huey LY, Segal DS. Effects of altering brain serotonin activity on human chronic pain. In: Bonica JJ, Albe-Fessard D, eds. *Advances in Pain Research and Therapy*. New York: Raven Press; 1976;1:601-606.
 14. Janowsky DS, Huey L, Storms L. Psychologic test responses and methylphenidate. *Cocaine and Other Stimulants*. New York: Plenum Press; 1976:575-687.
 15. Davis J, Janowsky DS, Casper R. Acetylcholine and mental disease. In: Usdin E, Barchas, eds. *NeuroRegulators in Psychiatric Disorders*. England: Oxford University Press; 1976:450-457.
 16. Janowsky DS, El-Yousef MK, Davis JM, Sekerke HJ. A cholinergic-adrenergic hypothesis of mania and depression. In: Segal DS, Yager J, Sullivan JL, eds. *Foundations of Biochemical Psychiatry*. Woburn, MA: Butterworth Publishers, Inc; 1976:230-236.
 17. Janowsky DS. Psychopharmacology. In: Abram HS, ed. *Basic Psychiatry for The Primary Care Physician*. Little, Brown; 1976:chap 12.
 18. Janowsky DS, Davis JM. Pharmacological challenge tests in psychiatric diagnosis: Physostigmine and methylphenidate. In: *Psychiatric Diagnosis: Exploration of Biological Predictors*. Spectrum Publications; 1978:263-27819.
- Davis JM, Janowsky D, El-Yousef MK. The effect of drug treatment on interpersonal styles of manic patients. *Neuro-Psychopharmacologicum: Tenth Collegium Internationale Neuro-Psychopharmacologicum*. Oxford, England: Pergamon Press; 1978;1:91-96.
20. Janowsky DS, Addario D, Schuckit M. *Psychopharmacology Case Studies*. New York: Medical Examination Publishing Co, Inc; 1978:1-181.
 21. Segal DS, Janowsky DS. Psychostimulant-induced behavioral effects: Possible models of schizophrenia. In: Lipton MA, Dimascio A, Killam KF, eds. *Psychopharmacology, A Generation of Progress*. New York: Raven Press; 1978:1113-1123.
 22. Davis JM, Janowsky D, Tamminga C, Smith RC. In: Jenden D, ed. Cholinergic mechanisms in schizophrenia, mania and depression. In: *Cholinergic Mechanisms in Psychopharmacology*. New York: Plenum Press; 1978:805-815.
 23. Judd LL, Janowsky DS, Segal DS, Huey LY. Naloxone related attenuation of manic symptoms in certain bipolar depressives. In: VanRee JM, Terenius L, eds. *Characteristics and Function of Opioids, Developments in Neuroscience*. Elsevier/North-Holland Biomedical Press; 1978;4:173-174.

24. Janowsky DS, Davis JM. Psychologic effects of cholinomimetic agents. In: Davis K, Berger P, eds. *Brain Acetylcholine and Neuropsychiatric Disease*. New York: Plenum Publishing Corp; 1979:3-14.
25. Janowsky DS, Abrams A, McCunney S, Groom G, Judd LL. Lithium and acetylcholine interactions. In: Davis KL, Berger PA, eds. *Brain Acetylcholine and Neuropsychiatric Disease*. New York: Plenum Publishing Corp; 1979:45-51.
26. Janowsky DS, Judd LL, Huey L, Segal D. Effects of naloxone in normal, manic, and schizophrenic patients: Evidence for alleviation of manic symptoms. In: Usdin E, Bunney W, Klein N, eds. *Endorphins in Mental Health Research*. London: MacMillan Press; 1979:435-447.
27. Judd LL, Segal DS, Janowsky DS. Behavioral effects of opioid peptides: Implications for future clinical research. In: Usdin E, Bunney W, Klein N, eds. *Endorphins in Mental Health Research*. London: MacMillan Press; 1979:448-451.
28. Judd LL, Hubbard B, Janowsky DS, Huey LY, et al.. Ethanol-lithium interactions in alcoholics. In: *Alcoholism and Affective Disorders*. New York: Spectrum Publishers Inc; 1979:109-135.
29. Janowsky DS, Judd LL, Huey L, Parker D, Liechner P. Methylphenidate induced changes in behavior, growth hormone, and prolactin. In: *Catecholamines: Basic and Clinical Frontiers*. Pergamon Press Inc; 1979:1902-1904.
30. Janowsky DS. *Neurotransmitter hypotheses of schizophrenia. Category 1 Continuing Medical Education*, sponsored by Lederle Labs; 1979;3.
31. Harris CM, Davis JM, Janowsky DS. Use of cholinergic drugs in mental illness. In: Barbeau A, Growden JH, Wurtman RJ, eds. *Choline and Lecithin in Brain Disorders (Nutrition and the Brain, Vol. 5)*. 1979:397-408.
32. Janowsky DS, Davis JM. Cholinergic mechanisms in mania and depressions: Questions of specificity. In: Belmaker R, vanPraag H, eds. *Mania: An Evolving Concept*. New York: Spectrum Publications; 1980:267-280.
33. Risch C, Janowsky DS. Pharmacology of analgesics, tranquilizers, sedatives, and hypnotic drugs. In: Karliner J, ed. *Coronary Care*. Churchill-Livingston Publishers; 1980:chap 33.
34. Janowsky DS. Menstrual and premenstrual mood disorders. In: *Phenomenology and Treatment of Psychophysiological Disorders*. New York: Spectrum Publications; 1982:chap 7.
35. Janowsky DS, Risch C, Huey L, Parker D, Davis J, Judd L. The cholinergic nervous system and depression. In: Mendels J, Amsterdam J, eds. *The Psychobiology of Affective Disorders*. Basel, Switzerland: Karger; 1980:83-98.
36. Grant I, Janowsky DS. Anticipating Psychiatric Crises. In: *Prevention in the Practice of Primary Care*. Addison-Wesley Publishing Co Inc; 1980:156-192.
37. Janowsky EC, Risch C, Janowsky DS. Psychotropic Agents. In: Smith NT, Miller RD, Corbascio AN, eds. *Drug Interactions in Anesthesia*. Philadelphia, PA: Lea and Febiger; 1981:chap 13.
38. Janowsky D, Clopton P, Huey L, Judd L. Effects of methylphenidate on interpersonal perceptions. In: Angrist B, et al., eds. *Recent Advances in Neuropsychopharmacology*. New York: Pergamon Press; 1981:75-82.

39. Risch SC, Janowsky DS, Huey LY. Plasma levels of tricyclic antidepressants and clinical efficacy. In: Enna SJ, Malick JB, Richelson E, eds. *Antidepressants: Neurochemical, Behavioral, and Clinical Perspectives*. New York: Raven Press; 1981:183-219.
40. Judd LL, Janowsky DS. Effects of narcotics and narcotic antagonists on affective disorder, schizophrenia and serum neurohormones. In: Emrich HM, ed. *Modern Problems in Pharmacopsychiatry: The Role of Endorphins in Neuropsychiatry*. Basel, Switzerland: S Karger AG Medical and Scientific Publishers; 1981:213-225
41. Janowsky D, Judd L. The effects of lithium on cholinergic mechanisms. In: Perris C, Struwe G, Janson B, eds. *Biological Psychiatry*. Amsterdam: Elsevier/North-Holland Biomedical Press; 1981:653-656.
42. Judd L, Janowsky D. Lithium: Effects on normal psychological and cognitive behavior. In: Perris C, Struwe G, Janson B, eds. *Biological Psychiatry*. Amsterdam: Elsevier/North-Holland Biomedical Press; 1981:657-660.
43. Janowsky DS, Judd LL. Effects of Opiate Antagonists and Agonists on Behavioral and Neuroendocrine Variables. In: Shah NS, Donald AG, eds. *Endorphins and Opiate Antagonists in Psychiatric Research: Clinical Implications*. New York: Plenum Publishing Corporation; 1982:chap 14.
44. Rausch J, Janowsky DS. Etiology of premenstrual tension. In: Frieman RC, ed. *Behavior and the Menstrual Cycle*. Marcel Dekker Inc; 1982;1:397-426.
45. Janowsky D, Risch S, Judd L, Parker D, Huey L. Physostigmine responses as markers in affective disorder patients. In: Hanin I, Usdin E, eds. *Biological Markers in Psychiatry and Neurology*. New York: Pergamon Press; 1982:253-260.
46. Risch SC, Janowsky DS, Kalin NH, Cohen RM, Aloji JA, Murphy DL. Cholinergic-B-endorphin hypersensitivity associated with depression. In: Hanin I, Usdin E, eds. *Biological Markers in Psychiatry and Neurology*. New York: Pergamon Press; 1982:269-278.
47. Janowsky DS, Risch SC, Parker D, Judd LL. Potential behavioral, neuroendocrine and cardiovascular markers of central cholinergic function. In: Corkin S, et al., eds. *Alzheimer's Disease: A Report of Progress*. New York: Raven Press; 1982:49-53.
48. Rausch J, Janowsky D, Risch S, Huey L, Swanson G. Physostigmine effect on platelet serotonin uptake. In: Ho BT, Usdin E, eds. *Serotonin in Biological Psychiatry*. Raven Press; 1982;34:326-327.
49. Janowsky DS. New psychopharmacological treatment concepts. In: *Anxiety and Anxiety in the Elderly in Contemporary Psychiatry*. Chicago, Illinois: Pragmaton Publications; 1982:12-20.
50. Janowsky DS, Risch SC, Judd LL, Parker DC, Kalin NH, Huey LY. Behavioral and neuroendocrine effects of physostigmine in affect disorder patients. In: Clayton PJ, Bennett JE, eds. *Treatment of Depression: Old Controversies and New Approaches*. New York: Raven Press; 1983:61-74.
51. Janowsky DS, Risch SC, Gillin JC. Adrenergic-cholinergic balance and the treatment of affective disorders. In: Sitaram N, ed. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*. Oxford, England: Pergamon Press Ltd; 1983;7:297-307.

52. Janowsky DS, Risch SC. Adrenergic-cholinergic balance and affective disorders: In: Rush AJ, Altshuler KZ, eds. *New Advances in the Treatment of Depression*. New York: Guilford Publications; 1983:85-101.
53. Risch SC, Janowsky DS. Cholinergic-adrenergic balance in affective disorders. In: Post RM, Ballenger JC, eds. *Neurobiology of the Mood Disorders*. Baltimore, MD: The Williams & Wilkins Company; 1984:652-663.
54. Risch SC, Janowsky DS, Parker D, Kalin NH, Aloji J, Cohen RM, Judd LL, Huey LY, Murphy DL. Neuroendocrine abnormalities in affective disorders: Possible cholinergic mechanisms. In: Post RM, Ballenger JC, eds. *Neurobiology of the Mood Disorders*. Baltimore, MD: The Williams & Wilkins Company; 1984:664-672.
55. Lisansky J, Strassman R, Janowsky D, Risch C. Drug-induced psychoses. In: Halbreich, Tupin, Pena, eds. *Transient Psychosis*. New York: Brunner/Mazel Inc; 1984:80-110.
56. Janowsky DS, Risch SC, Ziegler M, Kennedy B, Judd LL, Huey L. Central acetylcholine-catecholamine induced cardiovascular changes: A model of stress. In: Usdin E, Kvetnansky R, Axelrod J, eds. *Stress: The Role of Catecholamines and Other Neurotransmitters*. New York: Gordon and Breach; 1984;1:161-169.
57. Janowsky DS. Characterization of Adrenoceptors in the Brain and the Periphery: Summary. In: *Catecholamines: Basic and Peripheral Mechanisms*. Alan R Liss Inc; 1984:303-304.
58. Janowsky DS, Risch SC, Ziegler M, Kennedy B, Judd LL, Huey LY. Central cholinergic-noradrenergic interactions and blood pressure control. In: *Catecholamines: Basic and Peripheral Mechanisms*. New York: Alan R Liss Inc; 1984:327-335.
59. Janowsky DS and members of the Consensus Panel. *Electro-Convulsive Therapy*. 5(11), 1985. (consensus statement).
60. Janowsky DS, Risch SC, Judd LL, Huey LY, Parker DC. Brain cholinergic systems and the pathogenesis of affective disorders. In: Warburton D, Lal H, Singh MM, eds. *Central Cholinergic Mechanisms and Adaptive Dysfunctions*. New York: Plenum Press; 1985:309-333.
61. Risch SC, Janowsky DS. Limbic-hypothalamic-pituitary-adrenal axis dysregulation in melancholia. In: *Psychiatry*. Philadelphia, PA: JB Lippincott Co; 1985(rev 1992);3:chap 54.
62. Janowsky DS, Risch SC, Neborsky R. Strategies for studying neurotransmitter hypotheses of affective disorders. In: Cavenar JO Jr, ed. *Psychiatry*. Philadelphia, PA: JP Lippincott Company; 1985;3:chap 55.
63. Janowsky DS. Affective disorders. In: Rakel RE, ed. *Conn's Current Therapy*. Philadelphia, PA: WG Saunders Company; 1985:921-926.
64. Gillin JC, Sitaram N, Janowsky D, Risch C, Huey L, Storch FI. Cholinergic mechanisms in REM sleep. In: Wauquier A, ed. *Sleep: Neurotransmitters and Neuromodulators*. New York: Raven Press; 1985:153-164.
65. Risch SC, Janowsky DS, Gillin JC, Mott M, Huey LY. Measurement of ACTH and prolactin in the dexamethasone suppression test. Does it increase sensitivity and specificity? In: Burrows GD, Norman TR, eds. *Clinical and Pharmacological Studies in Psychiatric Disorders*. London: John Libby; 1985:150-154.

66. Janowsky D. Treatment of affective disorders in the elderly patient: Pharmacologic considerations. In: Maletta GJ, Pirozzolo FJ, eds. *Assessment and Treatment of the Elderly Neuropsychiatric Patient*. New York: Praeger; 1986;59-85.
67. Glick I, Janowsky DS, Salzman C, Shader RI. *A Model Psychopharmacology Curriculum for Psychiatric Residents*. American College of Neuropsychopharmacology; 1984.
68. Janowsky DS. Desipramine as an alternate therapy. In: *Consultations in depression: Perspectives on the clinical use of desipramine. Psychosomatics*. (Monograph), 1985(spring):15-19.
69. Janowsky DS. Psychopharmacologic Therapy. In: Kutash IL, Wolf A, eds. *Psychotherapist's Casebook*. San Francisco: Jossey-Bass Publishers, Inc; 1986:312-327.
70. Janowsky DS. A role for acetylcholine in mania. In: Swann A, ed. *Mania: New Research Findings and Treatment*. Washington, DC: American Psychiatric Press; 1986:60-77.
71. Janowsky DS, Risch SC, Gillin JC, Ziegler M, Kennedy P, Huey L. Central acetylcholine and stress-induced cardiovascular, neuroendocrine and behavioral changes: Effects of physostigmine and neostigmine. In: Hanin I, ed. *Dynamics of Cholinergic Function*. New York: Plenum Press; 1986;30:325-334.
72. Risch SC, Janowsky DS, Gillin JC. Muscarinic supersensitivity of anterior pituitary ACTH and beta-endorphin release in major depressive illness. In: Hanin I, ed. *Dynamics of Cholinergic Function*. New York: Plenum Press; 1986;30:335-343.
73. Janowsky DS, Risch SC, Berkowitz A, Turken A, Kennedy B, Drennan M. Central versus peripheral antagonism of cholinesterase inhibitor induced lethality. In: Hanin I, ed. *Dynamics of Cholinergic Function*. New York: Plenum Press; 1986;30:791-798.
74. Janowsky DS. Affective Disorders. In: Rakel RE, ed. *Conn's Current Therapy 1986*. Philadelphia: WB Saunders Company; 1986:913-918.
75. Gillin JC, Kripke DF, Risch SC, Janowsky DS. How sensitive and specific are the sleep disturbances and "sleep therapies" of depression. In: Shagrass C, et al., eds. *Biological Psychiatry*. New York: Elsevier Science Publishing Co, Inc; 1986:960-962.
76. Kripke DF, Mullaney DJ, Gillin JC, Risch SC, Janowsky DS. Phototherapy of non-seasonal depression. In: Shagrass C, et al., eds. *Biological Psychiatry*. New York: Elsevier Science Publishing Co, Inc; 1986:993-995.
77. Gillin JC, Kelsoe JR, Darko D, Kalin H, Risch SC, Janowsky DS. Current investigations of muscarinic supersensitivity in depression. In: Shagrass C, et al., eds. In: *Biological Psychiatry*. New York: Elsevier Science Publishing; 1986:1558-1559.
78. Janowsky DS, Risch SC, Berkowitz A, Turken A, Drennan M. Central Versus Peripheral Antagonism of Cholinesterase. In: Hanin I, ed. *Dynamics of Cholinergic Function*. Plenum Publishing Corporation; 1986:791-798.
79. Kripke DF, Gillin JC, Mullaney DJ, Risch SC, Janowsky DS. Treatment of major depressive disorders by bright white light for five days. In: Halaris A, ed. *Chronobiology and Neuropsychiatric Disorders*. New York: Pergamon Press; 1987:207-218.

80. Janowsky DS, Risch SC, Overstreet DH. Neurotransmitter-psychopharmacologic-neuroendocrine interactions in the study of the affective disorders. In: Halbreich U, ed. *Hormones and Depression*. New York: Raven Press; 1987:151-160.
81. Risch SC, Janowsky DS, Gillin JC, Kelsoe J, Ziegler M. Muscarinic mechanisms in neuroendocrine regulation and depression. In: Halbreich U, ed. *Hormones and Depression*. New York: Raven Press; 1987:207-228.
82. Janowsky DS, Addario D, Risch SC. *Psychopharmacology Case Studies*. New York: Guilford Press; 1987:1-259.
83. Janowsky DS, Risch SC. Role of acetylcholine mechanisms in the affective disorders. In: Meltzer HY, ed. *Psychopharmacology: A Third Generation of Progress*. New York: Raven Press; 1987:chap 53.
84. Glick ID, Janowsky DS, Salzman C, Shader RI. A model psychopharmacology curriculum for psychiatric residents. In: Meltzer HY, ed. *Psychopharmacology: A Third Generation of Progress*. New York: Raven Press; 1987:chap 138.
85. Janowsky DS, Golden RN, Risch SC. Cholinergic mechanisms in mood: Neuroendocrine aspects. In: Ganten D, Pfaff D, eds. *Current Topics In Neuroendocrinology*. New York: Springer Verlag; 1988;8:211-229.
86. Janowsky DS, Golden RN, Rapaport M, Cain JJ, Gillin JC. Neurochemistry of depression and mania. In: Georgotas A, Cancro R, eds. *Depression and Mania*. New York: Elsevier Science Publishing Co; 1988:244-264.
87. Golden RN, Evans DL, Janowsky DS. Involutional melancholia. In: Howells J, ed. *Modern Perspectives In the Psychiatry of the Affective Disorders*. New York: Brunner/Mazel; 1988:246-264.
88. Janowsky DS, Risch SC, Ziegler M. Cardiovascular and adrenomedullary effects of physostigmine: Mechanistic and diagnostic issues. In: *Progress In Catecholamine Research Part C: Clinical Aspects*. New York: Alan R. Liss; 1988:151-153.
89. Janowsky DS, Risch SC, Huey L, Kennedy B, Ziegler M. Acetylcholine-catecholamine interactions in stress and affective disorders: Comparison of the effects of physostigmine and neostigmine. *Perspectives In Psychopharmacology: A Collection of Papers in Honor of Earl Usdin*. New York: Alan R. Liss; 1988:301-313.
90. Janowsky DS, Risch SC, Gillin JC. Cholinergic involvement in affective illness. In: Sen AK, Lee T, eds. *Receptors and Ligands In Psychiatry*. London: Cambridge University Press; 1988;3:228-244.
91. Risch SC, Janowsky DS, Judd LL, Gillin JC, Mott MA, Rausch JL, Huey LY. Multiendocrine analyses in depression. In: Schatzberg AF, Nemeroff C, eds. *HPA Physiology and Pathophysiology*. New York: Raven Press; 1988:171-186.
92. Janowsky DS. Differential effects of physostigmine in alcoholics, alcoholics with affective disorders, and normals. In: Lerer B, Gershon S, eds. *New Directions In Affective Disorders*; New York: Springer-Verlag; 1989:79-81.
93. Risch SC, Judd LL, Gillin JC, Janowsky DS, McAdams LA, Golshan S. Neuroendocrine effects of intravenous ovine corticotropin-releasing factor and human growth hormone-releasing factor

- in affective disorder patients and normal controls. In: Lerer B, Gershon S, (eds) *New Directions in Affective Disorders*. New York: Springer-Verlag; 1989:262-271.
94. Overstreet DH, Janowsky DS. A cholinergic supersensitivity model of depression. In: Boulton AA, Baker GB, Martin-Iverson MT, eds. *Neuromethods: Animal Models In Psychiatry II*. Clifton, NJ: Humana Press; 1991;19:81-114.
 95. Overstreet DH, Rezvani AH, Pucilowski O, Janowsky DS, Kampov-Polevoi AB, Halikas JA. Biological correlates of ethanol intake in Fawn-Hooded-derived heterogeneous rats. In: Longo V, Serendenin S (eds.) *Biological Basis of Individual Sensitivity to Psychotropic Drugs*. Edinburgh, UK: Graffham Press Ltd., 1994:197-202.
 96. Kampov-Polevoi AB, Overstreet DH, Crosby RD, Rezvani AH, Janowsky DS, Halikas JA. saccharin-induced polydipsia as a predictor of voluntary alcohol intake in Wistar Rats. In: Longo V, Serendenin (eds.) *Biological Basis of Individual Sensitivity to Psychotropic Drugs*. Edinburgh, UK. Graffham Press Ltd., 1994: 293-298.
 97. Glick ID, Braff DL, Janowsky, DS. Short- and long-term psychopharmacological treatment strategies. In: Bloom, FE, Kupfer, DJ, (eds.) *Psychopharmacology: The Fourth Generation of Progress*. New York. Raven Press, Ltd., 1995, 839-847.
 98. Janowsky DS, Overstreet D. The role of acetylcholine mechanisms in the affective disorders. In: Bloom FE, Kupfer, DJ (eds) *Psychopharmacology: The Fourth Generation of Progress*. New York: Ravena Press, Ltd.; 1995:945-956.
 99. Janowsky DS, Rausch J, Halbreich U. The association among ovarian hormone, emotional disorders, other hormones and neurotransmitters. In: Halbreich U, Hamilton J, Jenswold J, eds. for *Psychopharmacology of Women: Sex, Gender, and Hormonal Considerations*. American Psychiatric Press Inc., Washington,D.C., London. 1996:85-106.
 100. Janowsky D, Morter S, Hong L, Howe L, Silva S. Myers Briggs Type Indicator differences between major depressive, bipolar, and alcohol/substance disorder patients and normals. *Mind, Body, and Personality: The Role of Type in Mental and Physical Health - Proceedings*, Center for Applications of Psychological Type, Gainesville, Florida, 1997:37-44.
 101. Janowsky DS, Overstreet DH. Mania: The role of cholinergic mechanisms and adrenergic/cholinergic interactions. *Mania*, American Psychiatric Press, Inc., Washington, D.C., London. Goodnick P, ed. 1997:135-155.
 102. Janowsky DS, Overstreet DH, Donhanich G. Acetylcholine and hormones. In: *Hormonal Modulation of Brain and Behavior*. U. Halbreich (ed.), American Psychiatric Press, Washington, DC, 1997 (in press)
 103. Janowsky DS. The Myers Briggs Type Indicator and Type A - Type B psychotherapists occupational interests. *Mind, Body, and Personality: The Role of Type in Mental and Physical Health - Proceedings*, Center for Applications of Psychological Type, Gainesville, Florida, 1997:45-51.
 104. Glick ID, Marder S, Janowsky D, Suppes T, DeBattista C. Short and long term psychopharmacologic treatment strategies. *A chapter for the section (Critical Analysis of Methods)*, in *Psychopharmacology: The Fourth Generation of Progress, CD/ROM Version*, (in press) 1997.

105. Janowsky DS, Hong L, Morter S, Silva S, Howe L. Underlying personality characteristics related to affective disorders and suicidality. *Neurobiology of Depression and Related Disorders*, Junichi Nomura (ed.), Mei University School of Medicine, Japan, 1998:2-30.
106. Janowsky DS. *Psychotherapy: Indications and Outcomes*. David S. Janowsky (ed.), American Psychiatric Press Inc., Washington, D.C. 1999:1-414.
107. Glick I, Doraiswamy P, Halper J, Janowsky D, Klein D, Lydiard B, Previn D, Ross P, Ward N, Zisooks, S. *American Society of Clinical Psychopharmacology, Inc., Model Psychopharmacology Curriculum for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology*, 1998:1-699.
108. Janowsky DS, Overstreet DH. Cholinergic dysfunction in mood disorders. In: *Basic Mechanisms and Therapeutic Implications of Bipolar Disorder*. Soares JC, Gershon S (eds.), Michel Dekker, Inc. New York, 1999.
109. Janowsky DS, Overstreet DH. The role of acetylcholine mechanisms in affective disorders. A Chapter for *Psychopharmacology: The Fourth Generation of Progress*. CD-ROM Version, 1999.
110. Janowsky DS. Therapist and patient personality characteristics and the nature, quality and outcome of psychotherapy: Focus on the Myers Briggs Type Indicator. In: *Psychotherapy Indications and Outcomes*. David S. Janowsky (ed.), American Psychiatric Press, Inc., Washington, D.C. 1999;47-69.
111. Janowsky DS. Thinking of neurotransmitters, moods and psychoses in the 1960s and 1970s. In: *The Triumph of Psychopharmacology and the Story of the CINP*. Ban TA (ed.), 2000.
112. Glick ID, Ellison J, Halper J, Janowsky DS, Lydiard RB, Osterheld J, Ross P, Zisook S. The ASCP Model Psychopharmacology Curriculum for Psychiatric Residency programs, Training Directors, and Teachers of Psychopharmacology, Second Edition. *The American Society of Clinical Psychopharmacology, 2001* (PO Box 2257, New York, NY 10116).
113. Janowsky DS, Overstreet D. The role of acetylcholine and its interactions with other neurotransmitters – neuromodulators in the affective disorders. In: *Handbook of Medical Psychiatry*. Soares JC, Gershon S (eds.), 347-362, 2002.
114. Janowsky DS. The bipolar spectrum: Focus on core personality characteristics. In: *Bipolar Disorder* (Evidence and Experience in Psychiatry). Maj M, Akiskal HS, Lopez-Ibor JJ, Sartorius (eds) Wiley, Chichester, 2002.
115. Janowsky DS. The history of psychotropic drugs in the United States. In: *Reflections on Twentieth-Century Psychopharmacology*. Ban TA, Healy D, Shorter E (eds.), Animula Publishing House, Budapest, Hungary, 2004, 77-82.
116. Janowsky DS, Overstreet DH. Cholinergic-muscarinic dysfunction in mood disorders. In: *Bipolar Disorders: Basic Mechanisms and Therapeutic Implications*, 2nd Edition. Soares JC, Young A (eds.), Michel Dekker, Inc., New York, 2007.

David S. Janowsky

December 17, 2015

